Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1734
mi
from 43215
Nampa, ID
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1734
mi
from 43215
Nampa, ID
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
288
mi
from 43215
Oak Brook, IL
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
288
mi
from 43215
Oak Brook, IL
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
345
mi
from 43215
Glen Burnie, MD
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
345
mi
from 43215
Glen Burnie, MD
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
246
mi
from 43215
Saginaw, MI
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
246
mi
from 43215
Saginaw, MI
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 43215
Franklin, OH
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 43215
Franklin, OH
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
426
mi
from 43215
Columbia, SC
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
426
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
925
mi
from 43215
Beaumont, TX
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
925
mi
from 43215
Beaumont, TX
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
307
mi
from 43215
Centreville, VA
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
307
mi
from 43215
Centreville, VA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
624
mi
from 43215
Shawnee Mission, KA
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
624
mi
from 43215
Shawnee Mission, KA
Click here to add this to my saved trials
Study of Hepatitis C Treatment During Pregnancy
Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  12/31/1969
Magee-Womens Hospital
165
mi
from 43215
Pittsburgh, PA
Study of Hepatitis C Treatment During Pregnancy
Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 12/31/1969
Magee-Womens Hospital
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Music and Feeding in NICU
The Mozart Effect and the Assessment of Weight Gain and Development of Feeding Skills in the NICU.
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System
386
mi
from 43215
Newark, DE
Music and Feeding in NICU
The Mozart Effect and the Assessment of Weight Gain and Development of Feeding Skills in the NICU.
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System
386
mi
from 43215
Newark, DE
Click here to add this to my saved trials
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
Status: Enrolling
Updated:  12/31/1969
Yale University
537
mi
from 43215
New Haven, CT
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
Status: Enrolling
Updated: 12/31/1969
Yale University
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Centering Pregnancy Care + Yoga for Diverse Pregnant Women
Centering Pregnancy Care + Yoga for Diverse Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University School of Nursing
344
mi
from 43215
Richmond, VA
Centering Pregnancy Care + Yoga for Diverse Pregnant Women
Centering Pregnancy Care + Yoga for Diverse Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University School of Nursing
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Combined Letrozole and Clomid in Women With Infertility and PCOS
Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Combined Letrozole and Clomid in Women With Infertility and PCOS
Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Richmond University Medical Center
471
mi
from 43215
Staten Island, NY
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Richmond University Medical Center
471
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
University of Colorado at Denver
1162
mi
from 43215
Denver, CO
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
University of Colorado at Denver
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
Indiana University
167
mi
from 43215
Indianapolis, IN
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
Indiana University
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
Boston University
643
mi
from 43215
Boston, MA
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
Boston University
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
Columbia University
481
mi
from 43215
New York, NY
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
Columbia University
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
344
mi
from 43215
Chapel Hill, NC
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
344
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated:  12/31/1969
Kinshasa School of Public Health
mi
from 43215
Kinshasa,
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
Status: Enrolling
Updated: 12/31/1969
Kinshasa School of Public Health
mi
from 43215
Kinshasa,
Click here to add this to my saved trials
Work of Breathing During Non-invasive Ventilation in Premature Neonates
Prospective Crossover Comparison of Work of Breathing During Non-invasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in Premature Neonates
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Work of Breathing During Non-invasive Ventilation in Premature Neonates
Prospective Crossover Comparison of Work of Breathing During Non-invasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in Premature Neonates
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix
Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
306
mi
from 43215
Winston-Salem, NC
Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix
Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
345
mi
from 43215
Baltimore, MD
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
995
mi
from 43215
Houston, TX
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
455
mi
from 43215
New Brunswick, NJ
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
455
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
643
mi
from 43215
Boston, MA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
394
mi
from 43215
Madison, WI
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Los Angeles County-USC Medical Center
1970
mi
from 43215
Los Angeles, CA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Los Angeles County-USC Medical Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Keck Medical Center of USC Pasadena
1965
mi
from 43215
Pasadena, CA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Keck Medical Center of USC Pasadena
1965
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia Cancer Center
277
mi
from 43215
Charlottesville, VA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia Cancer Center
277
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital-Winship Cancer Institute
436
mi
from 43215
Atlanta, GA
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital-Winship Cancer Institute
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials